Drug intelligence / Profile preview

DA-5218

Development stage: Phase 1
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-5218 is an investigational small molecule drug developed by Dong-A ST. It is being evaluated as an oral agent, with its primary development focused on metabolic disorders, specifically type 2 diabetes. The precise mechanism of action for DA-5218 has not been disclosed or remains unknown. As of the latest available information, it has undergone Phase 1 clinical trials in healthy volunteers to assess pharmacokinetics and safety profiles. There are no approved indications or known adverse events reported for this compound[1][3][7].

Beyond the preview

Go deeper on DA-5218.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5218.

Explore the full profile